Zenlabs Ethica Peer Comparison

BSE: 530697

₹28.25

₹-1.27 (-4.30%)

As on 23-Sep-2026IST

Market cap

₹18 Cr

Revenue (TTM)

₹50 Cr

P/E Ratio

--

P/B Ratio

2.3

Div. Yield

0 %

Edit

	Zenlabs Ethica	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Market cap (₹ Cr)	18	21,165	20,356	17,607	18,377
Revenue (₹ Cr)	50	2,287	1,682	3,230	2,570
Net Profit (₹ Cr)	-2.54	678.07	273.51	666.92	735.15
Net Margin (%)	-5.10	28.10	16.19	20.60	26.88
RoE (%)	-4.90	19.73	11.15	18.75	19.16
Price to Earnings	--	31.81	68.47	27.34	25.00
Price-To-Book	2.29	5.76	7.58	4.37	4.17

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Zenlabs Ethica	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Operating Revenue	49.62	2,287.33	1,682.47	3,229.67	2,569.77
Total Income	49.80	2,413.29	1,689.83	3,237.12	2,735.39
Total Expenditure	48.67	1,490.75	1,203.91	2,090.06	1,628.14
EBITDA	0.95	796.58	478.55	1,139.61	941.63
Depreciation	0.71	78.10	126.01	281.06	57.58
EBIT	0.25	718.48	352.55	858.55	884.05
Interest	0.76	0.88	52.11	190.64	7.69
Other Income	0.18	125.96	7.37	7.45	165.62
Exceptional Items	-2.08	0.00	12.16	-17.24	-49.16
Profit before Tax	-2.41	843.56	319.96	658.12	992.82
Provision for Tax	0.13	165.49	46.45	-8.80	257.67
Profit after Tax	-2.54	678.07	273.51	666.92	735.15

Liabilities (₹ Cr)

	Zenlabs Ethica	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Shareholder's Funds	8.51	3,586.42	2,591.20	3,902.67	4,202.90
Minority Interest	0.00	-12.71	0.00	-21.81	0.00
Non-Current Liabilities	1.57	28.74	266.35	1,392.75	91.50
Current Liabilities	27.12	385.94	848.06	2,077.10	627.48
Total Liabilities	40.62	3,207.85	3,310.68	6,865.52	4,911.11

Assets (₹ Cr)

	Zenlabs Ethica	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Non-Current Assets	1.55	1,291.22	2,525.44	5,617.77	770.28
Current Assets	35.10	2,585.66	1,109.77	1,539.85	3,803.22
Total Assets	40.62	3,207.85	3,310.68	6,865.52	4,911.11
Total Debt*	11.88	0.55	586.37	2,421.66	2.50
Net Current Assets	7.98	2,199.72	261.71	-537.25	3,175.74
Contingent Liabilities	0.07	0.64	76.22	51.96	363.79

Cashflow (₹ Cr)

	Zenlabs Ethica	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Cash From Operating Activities	3.83	432.37	132.27	1,065.01	659.75
Cash Flow from Investing Activities	0.14	-334.73	-199.13	-79.97	-71.34
Cash from Financing Activities	-3.08	-38.32	62.65	-881.32	-205.34
Net Cash Inflow / Outflow	0.88	59.32	-4.21	103.72	383.07

Ratios

Profitability Ratios

	Zenlabs Ethica	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
ROCE (%)	5.96	26.22	6.95	13.59	26.21
ROE (%)	-4.90	19.73	11.15	18.75	19.16
ROA (%)	-6.52	18.69	7.80	9.26	14.95
EBIT Margin (%)	0.50	31.41	20.95	26.58	34.40
Net Margin (%)	-5.10	28.10	16.19	20.60	26.88
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Zenlabs Ethica	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Revenue Growth (%)	-1.81	15.01	27.91	9.59	10.69
EBIT Growth (%)	-80.46	18.45	58.32	16.84	24.14
Net Profit Growth (%)	-1,076.54	19.61	149.56	62.68	-9.09
EPS Growth (%)	-279.69	17.73	-3.57	67.41	14.40
Book Value Growth (%)	2.98	23.77	30.63	10.19	17.30

Valuation Ratios

	Zenlabs Ethica	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Price / Earnings	-41.13	31.75	72.10	26.76	23.69
Price / Book Value	2.42	5.75	7.52	4.38	4.15
Dividend Yield (%)	0.00	0.29	0.06	0.00	1.88
EV/EBITDA	30.74	25.26	43.51	17.46	16.11
Market Cap (₹ Cr)	20.32	15,219.80	6,484.12	19,292.77	18,318.10

Solvency Ratios

	Zenlabs Ethica	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Debt to Equity	0.02	0.00	0.07	0.24	0.00
Short term debt to equity ratio	1.06	0.00	0.13	0.14	0.00
Current Ratio	1.29	6.70	1.31	0.74	6.06
Quick Ratio	0.74	5.59	0.88	0.53	5.31
Interest Coverage	-2.17	959.59	7.14	4.45	130.11

Operating Efficiency Ratios

	Zenlabs Ethica	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Debtors to sales (%)	31.65	36.10	30.84	21.07	7.07
Asset Turnover	1.28	0.63	0.48	0.45	0.52
Receivable days	142.89	110.70	118.15	54.06	29.10
Inventory Days	89.06	65.86	98.29	32.16	69.53
Payable days	129.56	105.88	128.16	140.91	76.77
Cash Conversion Cycle	102.39	70.68	88.28	-54.69	21.86

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly